Compare Citius Pharmaceuticals Inc (CTXR) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while ZIM Integrated Shipping Services Ltd trades at $24.47 (market cap $2.94B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 200.8× Citius Pharmaceuticals Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ZIM | |
|---|---|---|
Market Cap | $14.64M | $2.94B |
Sector | Health | Industrials |
52-Week High | $1.82 | $29.27 |
52-Week Low | $0.53 | $12.44 |
Enterprise Value | $10.86M | $6.79B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ZIM Integrated Shipping Services (ZIM) trades at $23.80, down 0.71% on the day, amid bearish technical signals and mixed fundamental performance. The stock faces pressure from regulatory setbacks to its Hapag-Lloyd merger, though recent news highlights rival takeover interest. Financially, 2025 revenue was $6.90B with net income of $479.20M, but 2026 projections show declining profitability. Analyst consensus is split evenly between Hold and Sell, with a price target of $16.75, well below current levels.
The outlook for ZIM is cautious due to merger uncertainty and weakening earnings. Investment opportunities exist if takeover bids materialize, but risks include regulatory hurdles, freight rate volatility, and cash flow pressures. The stock's current price trades at a discount to asset value, yet analyst skepticism and bearish technicals suggest limited near-term upside without positive deal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
